Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linzagolix PRIMROSE bone mineral density long-term follow-up
2021-000452-19Phase 3Completed
- Sponsor
- ObsEva SA
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of linzagolix in Fibromyoma (LM) (3 cohorts), sponsored by ObsEva SA. Primary endpoint: Change in lumbar spine, femoral neck, and total hip bone mineral density after end of treatment. Started Mar 2021; status: completed.
02
Drugs
linzagolix
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on 2021-000452-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000452-19.